Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1136781

	registered interest
	date	03/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Academic Health Science Networks
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government by what process, during the current development of policy options for Academic Health Science Centres (AHSC), potential new AHSCs can be considered in areas of England currently unrepresented by existing AHSCs.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL16931
	answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Department-designated Academic Health Science Centres (AHSCs) along with the Academic Health Science Networks (AHSNs) and the National Institute for Health Research (NIHR) Applied Research Collaborations (ARCs) are all important components of the country’s health research and innovation ecosystem.</p><p>The six current Department-designated AHSCs were made on the basis of an open competition, which was open to eligible National Health Service and University partnerships across England. The recommendations for designation were made to the Department by an international independent panel.</p><p>The remit of the Accelerated Access Collaborative (AAC) has recently been expanded to become the umbrella body across the United Kingdom health innovation eco-system. The AAC has been asked to consider the role of new AHSCs within the health system and to ensure that they complement the innovation landscape, rather than add further complexity to it.</p><p>It is not possible to provide specific details of the scope and nature of the new designation process at this stage given that the AAC is currently actively considering this. However, it is expected that the future designation process would be open to all NHS and University partnerships across England which meet the published specification to apply, including partnerships in areas of England where there is currently no Departmental-AHSC. As with the previous AHSC designation process, any future process will be run via a full and open competition, assessed by an independent expert panel. Rigorous conflict of interest policies will also be in place throughout the process for all involved to ensure any potential conflicts are dealt with appropriately.</p><p>The existing Departmental-AHSC designation will be extended until the end of March 2020 to enable a new designation process to be undertaken. The Department’s expectation is that AHSCs will play an increasingly important role in the health innovation and research landscape over the coming years.</p><p>As currently, the success of any newly designated AHSCs will require close interplay and cooperation between research infrastructure, including NIHR Biomedical Research Centres (BRCs) and the NIHR ARCs, and with the AHSNs and wider innovation landscape.</p><p>As part of annual monitoring of the existing Department-designated AHSCs, examples of innovations arising from them have been reported to have been made available to patients in the NHS. These include:</p><p>- The King’s Health Partners Heart Failure Service, which brings together clinical, research and educational expertise to deliver world class heart care in south London, helping people with heart failure live longer and with better quality of life;</p><p>- University College London Partners AHSC adoption of a Learning Health System to standardise data entry and allowing the widespread trialling of novel tools to detect atrial fibrillation early;</p><p>- The Manchester AHSC working with partners to align research around core health and social care priorities; and supporting the roll out of a single blood test driven decision-aid for patients presenting with chest pain at local emergency departments; and</p><p>- The roll out of the innovative Sleepio app by the Oxford AHSN to support those suffering from insomnia across Oxfordshire, Berkshire and Buckinghamshire.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16932 HL16934 question first answered 17/07/2019 16:29:08 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1136782

	registered interest
	date	03/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medicine: Research
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what the future relationship will be between Academic Health Science Networks, Academic Health Science Centres and Academic Research Collaborations with regard to the future applied health science ecosystem.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL16932
	answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Department-designated Academic Health Science Centres (AHSCs) along with the Academic Health Science Networks (AHSNs) and the National Institute for Health Research (NIHR) Applied Research Collaborations (ARCs) are all important components of the country’s health research and innovation ecosystem.</p><p>The six current Department-designated AHSCs were made on the basis of an open competition, which was open to eligible National Health Service and University partnerships across England. The recommendations for designation were made to the Department by an international independent panel.</p><p>The remit of the Accelerated Access Collaborative (AAC) has recently been expanded to become the umbrella body across the United Kingdom health innovation eco-system. The AAC has been asked to consider the role of new AHSCs within the health system and to ensure that they complement the innovation landscape, rather than add further complexity to it.</p><p>It is not possible to provide specific details of the scope and nature of the new designation process at this stage given that the AAC is currently actively considering this. However, it is expected that the future designation process would be open to all NHS and University partnerships across England which meet the published specification to apply, including partnerships in areas of England where there is currently no Departmental-AHSC. As with the previous AHSC designation process, any future process will be run via a full and open competition, assessed by an independent expert panel. Rigorous conflict of interest policies will also be in place throughout the process for all involved to ensure any potential conflicts are dealt with appropriately.</p><p>The existing Departmental-AHSC designation will be extended until the end of March 2020 to enable a new designation process to be undertaken. The Department’s expectation is that AHSCs will play an increasingly important role in the health innovation and research landscape over the coming years.</p><p>As currently, the success of any newly designated AHSCs will require close interplay and cooperation between research infrastructure, including NIHR Biomedical Research Centres (BRCs) and the NIHR ARCs, and with the AHSNs and wider innovation landscape.</p><p>As part of annual monitoring of the existing Department-designated AHSCs, examples of innovations arising from them have been reported to have been made available to patients in the NHS. These include:</p><p>- The King’s Health Partners Heart Failure Service, which brings together clinical, research and educational expertise to deliver world class heart care in south London, helping people with heart failure live longer and with better quality of life;</p><p>- University College London Partners AHSC adoption of a Learning Health System to standardise data entry and allowing the widespread trialling of novel tools to detect atrial fibrillation early;</p><p>- The Manchester AHSC working with partners to align research around core health and social care priorities; and supporting the roll out of a single blood test driven decision-aid for patients presenting with chest pain at local emergency departments; and</p><p>- The roll out of the innovative Sleepio app by the Oxford AHSN to support those suffering from insomnia across Oxfordshire, Berkshire and Buckinghamshire.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16931 HL16934 question first answered 17/07/2019 16:29:08 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1136783

	registered interest
	date	03/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medicine: Research
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what governance arrangements they have proposed for the newly designated Academic Research Collaborations.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL16933
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>Following, a new, open competition, the Government has recently announced National Institute of Health Research (NIHR) designation and funding for 15 Applied Research Collaborations (ARCs), with total funding of £135 million over five years from 1 October 2019.</p><p>Each NIHR ARC will have its own local governance arrangements in place, with the named Director of each NIHR ARC having responsibility, and authority over, the NIHR funding awarded to their National Health Service organisations through the scheme. Under the terms of the NIHR contract, the NIHR ARCs will be required to submit annual progress reports and can be subject site visits to evaluate progress, performance and identify key issues.</p><p>All NIHR ARCs are required to ensure that research is conducted in accordance with the United Kingdom Policy Framework for Health and Social Care Research and the Concordat to Support Research Integrity and the Governance Arrangements for Research Ethics Committees.</p><p> </p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 10:25:42 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1136784

	registered interest
	date	03/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Academic Health Science Networks
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of whether the innovations arising from the current phase of Academic Health Science Centres are being made available to patients throughout the NHS.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL16934
	answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Department-designated Academic Health Science Centres (AHSCs) along with the Academic Health Science Networks (AHSNs) and the National Institute for Health Research (NIHR) Applied Research Collaborations (ARCs) are all important components of the country’s health research and innovation ecosystem.</p><p>The six current Department-designated AHSCs were made on the basis of an open competition, which was open to eligible National Health Service and University partnerships across England. The recommendations for designation were made to the Department by an international independent panel.</p><p>The remit of the Accelerated Access Collaborative (AAC) has recently been expanded to become the umbrella body across the United Kingdom health innovation eco-system. The AAC has been asked to consider the role of new AHSCs within the health system and to ensure that they complement the innovation landscape, rather than add further complexity to it.</p><p>It is not possible to provide specific details of the scope and nature of the new designation process at this stage given that the AAC is currently actively considering this. However, it is expected that the future designation process would be open to all NHS and University partnerships across England which meet the published specification to apply, including partnerships in areas of England where there is currently no Departmental-AHSC. As with the previous AHSC designation process, any future process will be run via a full and open competition, assessed by an independent expert panel. Rigorous conflict of interest policies will also be in place throughout the process for all involved to ensure any potential conflicts are dealt with appropriately.</p><p>The existing Departmental-AHSC designation will be extended until the end of March 2020 to enable a new designation process to be undertaken. The Department’s expectation is that AHSCs will play an increasingly important role in the health innovation and research landscape over the coming years.</p><p>As currently, the success of any newly designated AHSCs will require close interplay and cooperation between research infrastructure, including NIHR Biomedical Research Centres (BRCs) and the NIHR ARCs, and with the AHSNs and wider innovation landscape.</p><p>As part of annual monitoring of the existing Department-designated AHSCs, examples of innovations arising from them have been reported to have been made available to patients in the NHS. These include:</p><p>- The King’s Health Partners Heart Failure Service, which brings together clinical, research and educational expertise to deliver world class heart care in south London, helping people with heart failure live longer and with better quality of life;</p><p>- University College London Partners AHSC adoption of a Learning Health System to standardise data entry and allowing the widespread trialling of novel tools to detect atrial fibrillation early;</p><p>- The Manchester AHSC working with partners to align research around core health and social care priorities; and supporting the roll out of a single blood test driven decision-aid for patients presenting with chest pain at local emergency departments; and</p><p>- The roll out of the innovative Sleepio app by the Oxford AHSN to support those suffering from insomnia across Oxfordshire, Berkshire and Buckinghamshire.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16931 HL16932 question first answered 17/07/2019 16:29:08 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1141957

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what are the drugs approved by NICE to treat HER2+ breast cancer; and what assessment they have made of the efficacy of such drugs.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL17501
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17502 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1141958

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pertuzumab
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what advice they provide to clinicians for the use of Pertuzumab rather than Herceptin for the treatment of HER2+ breast cancer.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL17502
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17501 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

167258

	registered interest
	date	02/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Nurses
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government when the National Research Unit for Nursing was disbanded; and which organisation was given responsibility for collecting statistics concerning the nursing profession.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL3359
	answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>The Department’s Policy Research Programme (PRP) funds research in three main ways:</p><p> </p><p> </p><p> </p><p>- long term programmes of research in academic policy research units, designed to meet the longer-term research needs of the Department as well as to provide a rapid response function;</p><p> </p><p>- large-scale initiatives, comprising linked groups of studies, providing a range of empirical evidence on a key policy area or issue; and</p><p> </p><p>- single projects and literature or scoping reviews.</p><p> </p><p> </p><p> </p><p>A PRP contract with the National Nursing Research Unit at King’s College London ended in December 2012. This funded a programme of policy-relevant nursing research including research based on analysis of new and existing datasets. The PRP does not currently fund research units in any specific health professions. The PRP will continue to fund new high quality research into policy and practice in nursing or other health professions using its policy research units and programme or other mechanisms as necessary. Details of research units and other research funded by the PRP is available on the website of the PRP Central Commissioning Facility:</p><p> </p><p> </p><p> </p><p>http://www.prp-ccf.org.uk/PRPFiles/Commissioned%20Projects%20-%20Nov%202014LaySummaries.pdf</p><p> </p> answering member printed Earl Howe question first answered 16/12/2014 14:28:36 answering member 2000 label Biography information for Earl Howe
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

167259

	registered interest
	date	02/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Professions
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government which health professions have retained a national research unit to collect data on the profession; and what is the current annual budget for each.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL3360
	answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>The Department’s Policy Research Programme (PRP) funds research in three main ways:</p><p> </p><p> </p><p> </p><p>- long term programmes of research in academic policy research units, designed to meet the longer-term research needs of the Department as well as to provide a rapid response function;</p><p> </p><p>- large-scale initiatives, comprising linked groups of studies, providing a range of empirical evidence on a key policy area or issue; and</p><p> </p><p>- single projects and literature or scoping reviews.</p><p> </p><p> </p><p> </p><p>A PRP contract with the National Nursing Research Unit at King’s College London ended in December 2012. This funded a programme of policy-relevant nursing research including research based on analysis of new and existing datasets. The PRP does not currently fund research units in any specific health professions. The PRP will continue to fund new high quality research into policy and practice in nursing or other health professions using its policy research units and programme or other mechanisms as necessary. Details of research units and other research funded by the PRP is available on the website of the PRP Central Commissioning Facility:</p><p> </p><p> </p><p> </p><p>http://www.prp-ccf.org.uk/PRPFiles/Commissioned%20Projects%20-%20Nov%202014LaySummaries.pdf</p><p> </p> answering member printed Earl Howe question first answered 16/12/2014 14:29:17 answering member 2000 label Biography information for Earl Howe
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

167260

	registered interest
	date	02/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Nurses: Student Wastage
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is the current attrition rate in numbers and percentage for student nurses in each year of their training at each higher education institute for each of the past three years.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL3361
	answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>Health Education England (HEE) took responsibility for commissioning pre-registration nurse education on 1 April 2013 and has a mandate deliverable to reduce attrition over the coming years. To replace the Department’s national data collection exercise, HEE has undertaken a data collection exercise to identify training output as a percentage of reported starters. The figures for the output, as a percentage of starters expressed as a projected attrition rate, in each of the last three years for which information is available are in the following table.</p><p> </p><p> </p><p> </p><p>Attrition as a percentage of reported starters:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Year course started</p></td><td><p>Projected attrition</p></td></tr><tr><td><p>2010-11</p></td><td><p>24.3%</p></td></tr><tr><td><p>2011-12</p></td><td><p>22.1%</p></td></tr><tr><td><p>2012-13</p></td><td><p>20.9%</p></td></tr></tbody></table><p> </p><p><em>Source: </em>Health Education England</p><p> </p><p> </p><p> </p><p>HEE is determined to ensure that there is a year on year reduction in levels of attrition and will be working with universities to deliver this, including ensuring a single definition of attrition and how it is managed.</p><p> </p> answering member printed Earl Howe question first answered 16/12/2014 16:26:44 answering member 2000 label Biography information for Earl Howe
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

167261

	registered interest
	date	02/12/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Nurses: Resignations
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is the attrition rate for registered nurses in each of the first three years following their qualification as a registered nurse.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL3362
	answer	answer is ministerial correction date of answer 15/12/2014 answer text <p>The Department does not hold information on the attrition rate for registered nurses.</p><p> </p> answering member printed Earl Howe question first answered 15/12/2014 12:52:56 answering member 2000 label Biography information for Earl Howe
	tabling member	4151 label Biography information for Lord Willis of Knaresborough